Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News & Events

Embroidary of lungs

Oxford lung cancer early detection trial reaches 400 participants

The SCOOT study seeks current and former smokers across England to provide blood samples for ongoing research aiming to improve lung cancer diagnosis.

Lungs

£1.7 million for vaccine to prevent lung cancer

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

MRI scanner

Funding to compare imaging modalities for liver cancer detection

The DeLIVER team will evaluate non-contrast-enhanced MRI and compare it to standard of care ultrasound in a cohort of patients under surveillance for liver cancer.

Schematic of antibodies being isolated by the nanoparticle technology

Ultrasensitive detection of p53 cancer biomarker

Professor Jason Davis and team have developed a new sensor to selectively and quantitatively measure p53 autoantibodies in the blood, levels of which are raised in a broad range of cancers.

Stills from colonoscopy videos showing outputs of polyp detection and segmentation algorithms.

Crowd-sourcing approach assesses current methods for improved automated detection and boundary mapping of colorectal cancer precursors

A computer vision challenge was set to objectively quantify the generalisability of polyp detection and mapping algorithms, and challenge participants to innovate novel methods.

Metformin in Li Fraumeni Syndrome trial logo

First patient recruited to MILI trial

Oxford’s first precision prevention cancer trial in people with Li Fraumeni Syndrome has opened to recruitment

Pathology image of dysplasia

Challenges for colorectal cancer risk stratification in people with IBD using histology

A team of pathologists were unable to validate a histology-based assessment of cancer risk in people with inflammatory bowel disease (IBD).

Registration desk at the OxCODE symposium

Oxford Centre for Early Cancer Detection Symposium 2023 – a recap

On Tuesday 5th December, the Oxford early cancer detection community gathered at the Mathematical Institute in Oxford to hear some highlights from OxCODE’s research in the past year and to discuss ideas for future projects.

Photo of an autumnal tree

Oxford Cancer Precision Prevention Symposium – a recap

To celebrate the launch of the UK’s first CRUK clinical trials unit dedicated to cancer precision prevention in Oxford, we held a research symposium that highlighted the spectra of Cancer Precision Prevention clinical programmes across the UK.

Person with monitor on wrist

University of Oxford Awarded £3 Million to Establish HealthTech Research Centre

The Nuffield Department of Primary Care Health Sciences wins an NIHR award for a new HealthTech Research Centre (HRC) to explore innovative Health Technology to enhance community and primary care.

The 2023 Early Detection of Cancer Conference, 10-12 October, Central Hall, Westminster, London, UK

OxCODE researchers at the Early Detection of Cancer Conference 2023

Oxford’s early detection research was featured at this annual event.

serenox-africa-logo

First private specialised haematology clinic and laboratory in sub-Saharan Africa launched

SerenOx Africa, led by Professor Anna Schuh, aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility also aims to provide early cancer detection for high-risk patients.

satisfai health logo

Collaboration announced to develop the use of AI to evaluate Barrett’s oesophagus

An agreement between Satisfai Health Inc and the University of Oxford will progress the automated assessment of Barrett’s oesophagus with the aim of determining patients most at risk of developing oesophageal cancer.

James Chettle, Masato Inoue and Eoghan Mulholland

OxCODE travel awards 2023

Congratulations to James Chettle, Masato Inoue and Eoghan Mulholland who have been awarded OxCODE funds to attend this year’s Early Detection of Cancer conference in London.

Metformin in Li Fraumeni Syndrome trial logo

MILI trial: the start of precision cancer prevention

Oxford’s first precision prevention cancer trial in people with Li Fraumeni Syndrome will also shed light on the mechanisms of cancer development in the general population

Image of red blood cells inside a blood vessel

Disentangling a long-standing link between inflammation and cancer progression

A study led by the Mead Group has demonstrated a previously unknown effect of chronic inflammation on TP53-mutant blood stem cells, shedding light on the progression of leukaemia.

James McCullagh, Monica Olcina, Bethan Psaila

OxCODE funding scheme awards 2023

Congratulations to James McCullagh, Monica Olcina, Bethan Psaila, and their collaborators who have been awarded funding in the fourth round of the OxCODE Funding Scheme.

Breast Self-Exam. A rear view of a woman performing a breast self-examination.

Model to predict 10-year risk of breast cancer

A team of researchers led by Professor Julia Hippisley-Cox have developed a new model that reliably predicts a woman's likelihood of developing and then dying of breast cancer within a decade.

Double funding success to improve detection and risk classification of myeloproliferative neoplasms (MPNs)

Blood Cancer UK and Cancer Research UK recognise the need and impact of artificial intelligence approaches developed by Professor Daniel Royston and Professor Jens Rittscher for early detection and assessment of these blood cancers.

DNA double helix

Identification of a molecular signature that correlates with patient prognosis in SETD2-mutated cancers

In a pan-cancer analysis spanning 24 different cancer types, researchers shed light on the relationship between SETD2, DNA methylation and cancer development.

Load More